Brazil- August 2024- Oncoclínicas is excited to announce its international expansion through a joint venture with Al Faisaliah Group, marking an entry into the Kingdom of Saudi Arabia.
This expansion is a strategic step towards realizing its core mission to “BEAT CANCER” on a global scale by extending our reach and sharing Oncoclínicas&Co’s specialized expertise.
Saudi Arabia has been notably advancing its healthcare infrastructure as part of its national vision to enhance the well-being of its citizens. Moreover, with these developments, Oncoclínicas&Co finds a unique opportunity to introduce its specialized oncological services to the Kingdom. Furthermore, Al Faisaliah Group has built a robust track record across various industries, including healthcare, life sciences, food and beverage, and electronics in Saudi Arabia. Their industry experience and extensive local know-how are pivotal to the success of its planned operations in Saudi Arabia.
The expansion will tailor services to meet the specific requirements of the Saudi Arabian healthcare sector, making advanced cancer care more accessible across the region and significantly improving healthcare delivery.
Also Read: Labcorp and Ultima Genomics Collaborate on WGS for Early Cancer Detection
The unit in Riyadh will focus on outpatient care in diagnostic medicine and treatments for chemotherapy and radiotherapy. It represents the internationalization of Oncoclínicas’ high-quality business and oncology care model on a global scale, reaffirming the company’s commitment to excellence and innovation in cancer treatment, as well as presenting an opportunity to tap into new oncology frontiers.
HRH Mohammed K.A. Al Faisal, President of Al Faisaliah Group and future Chairman of the JV, emphasized: “We’re joining forces to improve cancer care. Our aim is to become the top private cancer treatment center for a region of over 300 million people. We’ll offer advanced treatments and expert care to save lives and raise the bar in cancer treatment”.
“We are thrilled to expand our premier outpatient oncology treatment to the KSA and wider GCC nations,” said Ferrari. “Our innovative service model will provide cancer patients with greater access to best-in-class care, and our dynamic business model will provide our shareholders and partners with a strong foothold for growth in the region. Ultimately, it will strengthen our resolve to ‘BEAT CANCER!’”.
Also Read: Imfinzi Approved in the US for Resectable Lung Cancer Treatment
